Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Author(s):
Mulligen, E. van (0000-0003-1900-790X); Bour, S.S.; Goossens, L.M.A.; Jong, P.H.P. de; Rutten-van Mölken, M.; Helm-van Mil, A. van der
Published
2024
Publication type
Article / Letter to editor
TreatmentMethotrexateRheumatoid ArthritisEconomics
Date issued
2024-09-18
Language
English
Is part of
Annals of the Rheumatic Diseases
hdl
1887/4108563
doi
10.1136/ard-2024-226286